Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.27 +0.52 (+1.03%)
Streaming Delayed Price Updated: 1:31 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
News headline image
MarketBeat Week in Review – 06/08 - 06/12 ↗
Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum 
Via MarketBeat
Topics Economy Initial Public Offering
News headline image
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. 
Via MarketBeat
Topics Intellectual Property
News headline image
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market. 
Via The Motley Fool
Topics Regulatory Compliance
GSK PLC-SPON ADR (NYSE:GSK) Passes Quality-Focused Caviar Cruise Stock Screener with Strong Profitability and Cash Flow ↗
Via Chartmill
News headline image
This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why? ↗
Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗
Via MarketBeat
News headline image
Mondrian Dumps 5.5 Million Yum China Shares Worth $284.6 Million ↗
Yum China operates over 12,000 restaurants across 1,700 cities, serving quick-service and casual dining to mass-market consumers. 
Via The Motley Fool
News headline image
Nvidia Rival Cerebras Files for an IPO: What Investors Should Know ↗
Cerebras Systems is a fast-growing AI chipmaker whose customers include ChatGPT maker OpenAI, Amazon, and Meta Platforms. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering
News headline image
3 Bargain-Cheap Small Caps Worth a Second Look ↗
Via MarketBeat
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape
In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health... 
Via MarketMinute
Topics Artificial Intelligence Lawsuit
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report ↗
Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. 
Via Benzinga
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level... 
Via Finterra
Topics Intellectual Property
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir... 
Via MarketMinute
Topics Intellectual Property
News headline image
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
On February 2, 2026, AstraZeneca PLC (NYSE: AZN) officially rang the opening bell at the New York Stock Exchange, marking the completion of its high-profile transition from the Nasdaq. The move signals... 
Via MarketMinute
Topics ETFs
News headline image
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s... 
Via MarketMinute
Topics Earnings
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration... 
Via MarketMinute
Topics Earnings
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.